ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!SMMT Company Profile and Key Details
Summit Therapeutics Inc.
SMMT Stock Price Chart
Stock Price Today
Summit Therapeutics Inc. (SMMT) stock declined over -4.08%, trading at $22.12 on NASDAQ, down from the previous close of $23.06. The stock opened at $23.80, fluctuating between $21.81 and $24.18 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Company Information
| Employees | 105 |
| Beta | -0.88 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | -1% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Summit Therapeutics Inc. (NASDAQ: SMMT) stock price is $22.12 in the last trading session. During the trading session, SMMT stock reached the peak price of $24.18 while $21.81 was the lowest point it dropped to. The percentage change in SMMT stock occurred in the recent session was -4.08% while the dollar amount for the price change in SMMT stock was -$0.94.
The NASDAQ listed SMMT is part of Biotechnology industry that operates in the broader Healthcare sector. Summit Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Anne Heatherington
Head of Clinical Devel. and Quantitative Sciences
Mr. Campbell Hair
Head of HR?
Ms. Michelle Avery
Director of Investor Relations
Mr. Will Black
Head of Information Technology?
Mr. Robert W. Duggan
Executive Chairman
Dr. Mahkam Zanganeh D.D.S., M.B.A., MBA
Chief Executive Officer, Pres & Director
Mr. Ankur Dhingra
Chief Financial Officer
Dr. Urte Gayko Ph.D.
Head of Regulatory Affairs, Quality Assurance & Safety
Prof. Dame Kay Davies DBE, FRS CBE
Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor
Dr. Elaine Carla Stracker J.D., Ph.D.
Head of Compliance? & Gen. Counsel
Ms. Shelley D. Spray
Head of Corporation Education, Communications & Creative?
Ms. Abby Guzman Murphy
Head of HR
Ms. Divya Chari
Head of Global Clinical Operations
Mr. Dave Gancarz
Senior Vice President of Stakeholder Relations, Bus. Devel. & Corporation Strategy?
SMMT's closing price is 953.33% higher than its 52-week low of $2.10 where as its distance from 52-week high of $33.89 is -34.73%.
Number of SMMT employees currently stands at 105.
Official Website of SMMT is: https://www.summittxinc.com
SMMT could be contacted at phone 617 514 7149 and can also be accessed through its website. SMMT operates from One Broadway, Cambridge, MA 02142, United States.
SMMT stock volume for the day was 3.32M shares. The average number of SMMT shares traded daily for last 3 months was 2.23M.
The market value of SMMT currently stands at $16.30B with its latest stock price at $22.12 and 737.09M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com